{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-080470","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2025-08-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.416639+00:00","generated_at":"2026-05-17T11:09:09.493396+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Theravance settles YUPELRI patent litigation with Cipla; generic launch date April 23, 2039","bullets":["Settlement resolves Hatch-Waxman patent litigation on YUPELRI (revefenacin) inhalation solution.","Cipla granted royalty-free license to market generic version in U.S. on or after April 23, 2039.","Settlement subject to review by U.S. DOJ and FTC as required by law.","Patent litigation remains pending against Mankind Pharma Ltd. and affiliates (another ANDA filer)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-080470","json":"https://secwatch.observer/filing/0001104659-25-080470.json","markdown":"https://secwatch.observer/filing/0001104659-25-080470.md","text":"https://secwatch.observer/filing/0001104659-25-080470.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465925080470/0001104659-25-080470-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465925080470/tm2523736d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T11:09:09.493396+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}